Polaryx Therapeutics, Inc. (PLYX) News
Track canonical SquawkNews coverage tagged to PLYX, Polaryx Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Polaryx Therapeutics names Will Charlton chief medical officer
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as chief medical officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.
REGULATION | Sep 01, 2026, 08:44 PM UTC
L
Polaryx Therapeutics appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics appointed Dr. Will Charlton as Chief Medical Officer.
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
Polaryx Therapeutics advances operational readiness for SOTERIA Phase 2 basket trial
Polaryx Therapeutics (PLYX) says it is advancing operational readiness for its SOTERIA Phase 2 basket trial.
EQUITY | Aug 25, 2026, 12:30 PM UTC
L
Analysts initiate coverage on ACHV, ALGM, KZIA, MTSI, PLYX, SBSW
Several brokers initiate or reiterate bullish coverage on ACHV, ALGM, KZIA, MTSI, PLYX and SBSW, including overweight, buy and strong buy ratings.
EQUITY | Aug 13, 2026, 10:50 AM UTC